Posts in Uncategorized

Pharmaceutical Development in Module 3.2.P.2: Telling the Story Behind the Formulation

Section 3.2.P.2 is where an applicant explains why the medicine is formulated, manufactured and packaged the way it is. Written well, it turns a set[…]

EU Module 1 and the Electronic Application Form: Getting the Regional Part Right

Module 1 is the only part of the CTD that is not harmonised internationally, and it is where many otherwise strong dossiers stumble. For EU[…]

The Common Technical Document Explained: How Modules 1 to 5 Fit Together

Every marketing authorisation application in the EU is built on the same skeleton: the Common Technical Document (CTD). Understanding how its five modules relate to[…]

Cross-Border Collaboration on Pricing and HTA: What Valletta, Beneluxa and the Nordic Model Mean for Greece

Pricing and reimbursement remain national decisions in the EU, but they are no longer taken in isolation. Since the mid-2010s, groups of Member States have[…]

Core Safety Information and the SmPC: Keeping Product Labels Aligned With the Safety Profile

Every marketing authorisation holder is legally required to keep its product information up to date with current scientific knowledge. In practice, that obligation depends on[…]

Radiopharmaceuticals and Theranostics: Regulatory and Access Considerations for a Growing Field

Radiopharmaceuticals are moving from diagnostic imaging into targeted therapy. Radioligand therapies and theranostic pairs, where one molecule is used both to image and to treat,[…]

The Revised GMP Annex 19: Reference and Retention Samples After September 2026

For the first time in twenty years, the European Commission has revised Annex 19 of the EU GMP Guide on reference and retention samples. The[…]

Product Complaints and Quality Defects: Getting EU GMP Chapter 8 Right

Every complaint about a medicine, whether a cracked vial, an unusual smell or a missing leaflet, can be the first sign of a wider quality[…]

Business Continuity for the Pharmacovigilance System: Keeping Safety Reporting Running When Things Go Wrong

Pharmacovigilance obligations continue through a cyber attack, an IT outage, a vendor failure or the unexpected absence of the QPPV. Expedited reporting timelines still run,[…]

Medication Errors in Pharmacovigilance: Recording, Reporting and Preventing Harm

Medication errors are among the most preventable sources of harm in the use of medicines, and EU pharmacovigilance law brings them explicitly into scope. For[…]